Screener
Inspire Medical Systems INSP Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inspire Medical Systems in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Inspire Medical Systems’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001609550-26-000023
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Revenue | $204,583 | $201,317 |
| Less: (a) | ||
| Cost of goods sold | 27,671 | 30,709 |
| Research and development expense | 25,826 | 27,803 |
| Selling, general and administrative expense (excluding advertising expense) | 130,558 | 123,349 |
| Advertising expense | 21,646 | 20,941 |
| Operating (loss) | (1,118) | (1,485) |
| Other income (b) | (3,515) | (5,644) |
Item 1. Financial Statements.
FAQ
- What is Inspire Medical Systems's business segments — R&D?
- Inspire Medical Systems (INSP) reported business segments — R&D of $25.83M in Q1 2026.
- How has Inspire Medical Systems's business segments — R&D changed year-over-year?
- Inspire Medical Systems's business segments — R&D decreased by 7.1% year-over-year, from $27.8M to $25.83M.
- What is the long-term trend for Inspire Medical Systems's business segments — R&D?
- Over 3 years (2022 to 2025), Inspire Medical Systems's business segments — R&D has grown at a 14.5% compound annual growth rate (CAGR), from $68.65M to $103.17M.
- What does business segments — R&D mean?
- Captures expenditures dedicated to the innovation, design, and clinical testing of new or improved medical technologies. This investment is critical for maintaining a competitive advantage in the neurostimulation market and ensuring long-term product pipeline viability.
Ask your AI about Inspire Medical Systems's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude